Physician profile
Sean Rea
NPI 1982098604
$383.58
in general payments reported to CMS, 2019-2025
10 companies · $14.11 in 2025
The $14.11 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.12 · 2020: $49.85 · 2021: $133 · 2022: $25.70 · 2023: $86.71 · 2025: $14.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $100.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $141.91 | 2021-2023 | |
| Pfizer INC. | $48.32 | 2021 | |
| Glaxosmithkline, LLC. | $37.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.56 | 2021-2022 | |
| Allergan, INC. | $30.67 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $29.90 | 2019-2020 | |
| Eisai INC. | $21.71 | 2021 | |
| Astellas Pharma US INC | $14.68 | 2020 | |
| Novo Nordisk INC | $14.11 | 2025 | |
| Gilead Sciences, INC. | $11.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Rea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.